Abstracts

USING MULTISTATE MODELS TO DISENTANGLE MORTALITY & LOSS TO FOLLOW-UP IN HIV+ PATIENTS

Estimating mortality in HIV-positive patients starting antiretroviral therapy (ART) is challenging, as clinics often face substantial loss to follow-up (LTFU). Many studies ignore LTFU, leading to biased estimates. Others correct for LTFU, but conventional methods give pooled estimates, which makes it impossible to asses risk factors and mortality estimates separately for those LTFU and remaining…

EXCESS MORTALITY AFTER CANCER DIAGNOSIS IN PERSONS WITH HIV

Persons with HIV (PWH) may have reduced survival after a cancer diagnosis compared with uninfected persons, yet prior studies are limited by insufficient control for confounding from access to care and other comorbidities, and do not often account for the increased background mortality rate of PWH. We conducted a cohort study during 2000-2016 of adult…

EXCESS MORTALITY AMONG PLWH WITH MULTIMORBIDITY COMPARED TO HIV-NEGATIVE CONTROLS

Antiretroviral therapy (ART) and gains in life expectancy have increased the likelihood of people living with HIV (PLWH) developing comorbidities. We examined which chronic comorbidities, experienced in isolation or in combination, led to higher mortality rates among PLWH compared to HIV-negative controls. Secondarily, we assessed the impact of multimorbidity on all-cause mortality among PLWH. This…

SEX-SPECIFIC ANALYSES IN ORAL ABSTRACTS FROM CROI 2019

Globally, women account for more than half of persons living with HIV (PWLH), yet remain underrepresented in research. Starting in 2018, CROI guidelines specifically recommended reporting of sex distribution and sex-adjusted analyses, but formal review showed rates of such reporting among CROI 2018 oral abstracts were low. Members of the Women’s Health Inter-Network Scientific Committee…

HIGH PROBABILITY OF SURVIVAL IN PATIENTS WHO MAINTAIN VIRAL LOADS

It is unclear whether low, detectable viral load (VL), observed as viral blips and low-level viremia, impacts risk of death. Our objective was to estimate mortality risk after initial suppression in patients who maintained VLs <200 copies/mL while in care at NA-ACCORD clinical sites in 2007–2016. We followed adults who newly initiated ART and achieved initial…